S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:MNMD

Mind Medicine (MindMed) (MNMD) Stock Price, News & Analysis

$8.68
-0.23 (-2.58%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$8.31
$9.00
50-Day Range
$4.38
$11.75
52-Week Range
$2.41
$12.22
Volume
1.52 million shs
Average Volume
1.95 million shs
Market Capitalization
$609.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.20

Mind Medicine (MindMed) MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
190.3% Upside
$25.20 Price Target
Short Interest
Bearish
26.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Mind Medicine (MindMed) in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$219,422 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.72) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

584th out of 907 stocks

Medicinals & Botanicals Industry

4th out of 8 stocks

MNMD stock logo

About Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company working to develop therapies and treatments based on psychoactive substances. The company develops novel products including psychoactive substances and digital medicine to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Digital medicine is the use of technology to measure and intervene in the service of human health and is a budding industry of its own. The company has 10 compounds in pre-clinical or clinical trials and 4 are on track to advance to Phase 1. The company is headquartered in Vancouver, Canada.

Mind Medicine’s pipeline of drug candidates is based on emerging science that more than suggests psychoactive substances can be used to relieve stress and anxiety disorders in the brain. Among the many potential uses for these drugs is the treatment of anxiety and stress related to PTSD and secondary stress disorders related to the treatment of people suffering from stress and anxiety-related disorders. Psychoactive compounds have also been shown to be effective in treating autism, pain, and social disorders.

The company’s treatments are focused on neuroplasticity or the fact our brain function is tied to its structure and the structure of our brains can change over time. When used in the proper context, Mind Medicine’s treatments aid the restructuring of brain activity and how it organizes information by catalyzing plasticity. In some cases, patients under treatment learn to make positive associations in relation to stress-inducing stimuli while under the influence of the treatments.

In addition to plasticity, psychoactive drugs like LSD, psilocybin, and DMT have been shown to have experiential effects such as lowering mental barriers and reducing defensive and often reflexive mechanisms that can be an impediment to healing.

Among the benefits of using psychoactive compounds versus traditional therapeutics are the speed of efficacy and greatly reduced side effects. Psychoactive drugs can produce positive effects in patients with the first use while it may take weeks for the current treatments to take effect and they come with many side effects. In some cases, side effects of mainstream treatments include an increase in suicidal behavior.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain. MM-120 is LSD D-tartrate. MM-110 is a nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine also develops MM-402 which is for the treatment of core symptoms of autism spectrum disorder. This treatment is based on MDMA and improves sociability in autistic patients without stimulants and is shown to have superior safety and tolerability.

 

MNMD Stock Price History

MNMD Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap Up to $9.67
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 3.2%
Niloufar Banisaied the Beauty & Brains
MNMD Apr 2024 13.000 put
MNMD Apr 2024 7.000 put
MNMD Apr 2024 15.000 call
MNMD Jun 2024 17.000 call
MNMD Aug 2024 9.000 call
MNMD Aug 2024 6.000 put
MNMD Apr 2024 17.000 call
MNMD Jan 2025 22.000 call
MNMD May 2024 9.000 call
MNMD Apr 2024 3.000 put
See More Headlines
Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MNMD
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$25.20
High Stock Price Target
$75.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+190.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-95,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.90 per share

Miscellaneous

Free Float
68,785,000
Market Cap
$609.94 million
Optionable
Optionable
Beta
2.81
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Robert Barrow (Age 35)
    CEO & Director
    Comp: $956.1k
  • Mr. Schond L. Greenway M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $343.28k
  • Dr. Daniel Rollings Karlin M.A. (Age 43)
    M.D., Chief Medical Officer
    Comp: $663.63k
  • Dr. Miriam Halperin Wernli Ph.D. (Age 71)
    Executive President
    Comp: $552.46k
  • Dr. Scott M. Freeman M.D. (Age 67)
    Co-Founder & Clinical Advisor
    Comp: $316.6k
  • Mr. Leonard Latchman
    Co-founder
  • Ms. Carrie F. Liao CPA
    CGMA, VP & Chief Accounting Officer
  • Mr. Mark R. Sullivan J.D. (Age 53)
    Chief Legal Officer & Corporate Secretary
  • Dr. Francois P. Lilienthal M.B.A.
    M.D., Chief Commercial Officer

MNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNMD shares.
View MNMD analyst ratings
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price target for 2024?

6 brokers have issued 12-month price objectives for Mind Medicine (MindMed)'s shares. Their MNMD share price targets range from $7.00 to $75.00. On average, they predict the company's stock price to reach $25.20 in the next twelve months. This suggests a possible upside of 190.3% from the stock's current price.
View analysts price targets for MNMD
or view top-rated stocks among Wall Street analysts.

How have MNMD shares performed in 2024?

Mind Medicine (MindMed)'s stock was trading at $3.66 at the beginning of 2024. Since then, MNMD stock has increased by 137.2% and is now trading at $8.68.
View the best growth stocks for 2024 here
.

Are investors shorting Mind Medicine (MindMed)?

Mind Medicine (MindMed) saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,230,000 shares, an increase of 23.2% from the March 15th total of 5,870,000 shares. Based on an average daily volume of 2,080,000 shares, the short-interest ratio is currently 3.5 days. Approximately 26.8% of the shares of the company are short sold.
View Mind Medicine (MindMed)'s Short Interest
.

When is Mind Medicine (MindMed)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MNMD earnings forecast
.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) issued its earnings results on Wednesday, February, 28th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.11.

What ETF holds Mind Medicine (MindMed)'s stock?

AdvisorShares Psychedelics ETF holds 112,717 shares of MNMD stock, representing 14.81% of its portfolio.

When did Mind Medicine (MindMed)'s stock split?

Mind Medicine (MindMed)'s stock reverse split before market open on Monday, August 29th 2022. The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNMD) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners